We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Complete Clinical Responders to Definite Chemoradiation in Esophageal Cancer : a Survival Analysis (CRCRT-EC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01525953
Recruitment Status : Completed
First Posted : February 3, 2012
Last Update Posted : February 3, 2012
Information provided by (Responsible Party):
Centre Oscar Lambret

Brief Summary:
The aim of this study is to identify prognostic factors for outcome in patients being complete clinical responders with chemoradiation or radiation for esophageal cancer

Condition or disease Intervention/treatment
Esophageal Cancer Drug: Chemotherapy Radiation: Radiotherapy

Study Type : Observational
Actual Enrollment : 110 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Predictors of Survival for Complete Clinical Responders to Definite Chemoradiation or Radiation Therapy for Esophageal Cancer
Study Start Date : January 2012
Primary Completion Date : January 2012
Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Intervention Details:
    Drug: Chemotherapy
    Chemotherapy according to standard
    Radiation: Radiotherapy
    Radiotherapy according to local standard

Primary Outcome Measures :
  1. Identification of prognostic factors for overall survival [ Time Frame: From date of treatment until death, assessed up to 10 years ]
    Correlation between survival and baseline,clinical and treatment characteristics

Secondary Outcome Measures :
  1. Patterns of treatment failure [ Time Frame: From date of treatment until treatment failure, assessed up to 10 years ]
    Type of recurrence : local, regional, distant.

  2. Disease-free survival [ Time Frame: From date of treatment until progression or death, assessed up to 10 years ]
    Time between the end of treatment and the occurence of progression

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient treated for esophageal cancer in the Northern France Cancer Center from january 1998 to december 2003

Inclusion Criteria:

  • localized or locally advanced esophageal cancer
  • patient who underwent definite chemoradiation or radiation
  • patient with complete clinical response

Exclusion Criteria:

  • metastatic disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01525953

Centre Oscar LAMBRET
Lille, France, 59000
Sponsors and Collaborators
Centre Oscar Lambret
Principal Investigator: Antoine ADENIS, MD, PhD Centre Oscar Lambret

Responsible Party: Centre Oscar Lambret
ClinicalTrials.gov Identifier: NCT01525953     History of Changes
Other Study ID Numbers: CRCRT-EC
First Posted: February 3, 2012    Key Record Dates
Last Update Posted: February 3, 2012
Last Verified: February 2012

Keywords provided by Centre Oscar Lambret:
esophageal cancer

Additional relevant MeSH terms:
Esophageal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases